XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.4

BUSINESS COMBINATIONS (Tables)

12 Months Ended

Sep. 30, 2021

Business Acquisition [Line Items]

Schedule of unaudited pro forma information

​

​	​	​	​	​	​
​	Twelve Months		​	Twelve Months
​	Ended		​	Ended
​	September 30, 2021			September 30, 2020
Total revenues	$	104,084	​	$	81,739
​	​		​	​	​
Net income		8,741	​		335
​			​		​

Pre-Clinical Research Services, Inc.

Business Acquisition [Line Items]

Schedule of purchase price allocation

​

​	​	​	​
​	​	Allocation as of
​	​	September 30, 2021
Assets acquired and liabilities assumed:		​
Accounts receivable	​	$	578
Property and equipment	​		2,836
Unbilled revenues	​	​	162
Prepaid expenses	​		27
Intangible assets	​	​	2,081
Goodwill	​	​	751
Accounts payable	​	​	(109)
Accrued expenses	​		(118)
Customer advances	​		(351)
​	​	$	5,857

HistoTox Labs

Business Acquisition [Line Items]

Schedule of purchase price allocation

​

​	​	​	​
​	​	Preliminary
​	​	Allocation as of
​	​	September 30, 2021
Assets acquired and liabilities assumed:		​
Accounts receivable	​	$	982
Unbilled revenues	​	​	337
Operating lease ROU asset (i)	​	​	2,239
Property and equipment	​		4,021
Intangible assets	​	​	8,500
Other assets	​	​	25
Goodwill (ii)	​	​	9,129
Accounts payable	​	​	(132)
Accrued expenses	​	​	(266)
Customer advances	​	​	(207)
Operating lease liability (i)	​		(2,239)
​	​	$	22,389

(i) Reflects the estimated right of use asset and associated liability to align with Inotiv accounting policy.

(ii) The preliminary estimates are based on the data available to Inotiv and may change upon completion of the final purchase price allocation. Any change in the estimated fair value of the assets and liabilities acquired will have a corresponding impact on the amount of the goodwill. In addition, a change in the amount of property, plant, and equipment and other identifiable intangible assets will have a direct impact on the amount of amortization and depreciation recorded against income in future periods. The impact of any changes in the purchase price allocation may have a material impact on the amounts presented in this pro forma condensed combined financial information.

Bolder BioPATH

Business Acquisition [Line Items]

Schedule of purchase price allocation

​

​	​	​	​
​	​	Preliminary
​	​	Allocation as of
​	​	September 30, 2021
Assets acquired and liabilities assumed:		​
Accounts receivable	​	$	2,258
Unbilled revenues	​	​	1,798
Prepaid expenses	​		6
Operating lease ROU asset (i)	​	​	2,750
Property and equipment	​		6,609
Intangible asset	​	​	12,500
Other assets	​	​	70
Goodwill (ii)	​	​	36,223
Accounts payable	​	​	(159)
Accrued expenses	​		(294)
Deferred revenue	​	​	(662)
Deferred tax liability	​	​	(4,867)
Operating lease liability (i)	​		(2,750)
​	​	$	53,482

(i) Reflects the estimated right of use asset and associated liability to align with Inotiv accounting policy.

(ii) The preliminary estimates are based on the data available to Inotiv and may change upon completion of the final purchase price allocation. Any change in the estimated fair value of the assets and liabilities acquired will have a corresponding impact on the amount of the goodwill. In addition, a change in the amount of property, plant, and equipment and other identifiable intangible assets will have a direct impact on the amount of amortization and depreciation recorded against income in future periods. The impact of any changes in the purchase price allocation may have a material impact on the amounts presented in this pro forma condensed combined financial information.

​

Gateway Pharmacology Laboratories LLC

Business Acquisition [Line Items]

Schedule of purchase price allocation

​

​	​	​	​
​	​	Preliminary
​	​	Allocation as of
​	​	September 30, 2021
Assets acquired and liabilities assumed:		​
Accounts receivable	​	$	422
Operating lease ROU asset (i)	​	​	120
Property and equipment	​		359
Intangible asset	​	​	100
Other assets	​	​	9
Goodwill (ii)	​	​	2,207
Accounts payable	​	​	(54)
Accrued expenses	​	​	(72)
Deferred tax liability	​	​	(118)
Operating lease liability (i)	​	​	(120)
​	​	$	2,853

(i) Reflects the estimated right of use asset and associated liability to align with Inotiv accounting policy.

(ii) The preliminary estimates are based on the data available to Inotiv and may change upon completion of the final purchase price allocation. Any change in the estimated fair value of the assets and liabilities acquired will have a corresponding impact on the amount of the goodwill. In addition, a change in the amount of property, plant, and equipment and other identifiable intangible assets will have a direct impact on the amount of amortization and depreciation recorded against income in future periods. The impact of any changes in the purchase price allocation may have a material impact on the amounts presented in this pro forma condensed combined financial information.

BioReliance Corporation

Business Acquisition [Line Items]

Schedule of purchase price allocation

​

​	​	​	​
​	​	Preliminary
​	​	Allocation as of
​	​	September 30, 2021
Assets acquired and liabilities assumed:		​
Property and equipment	​	$	175
Intangible asset	​	​	640
​	​	$	815

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_PreClinicalResearchServicesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_HistotoxLabsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_BolderBioPTHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_GatewayPharmacologyLaboratoriesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=notv_BioRelianceCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: